Search results for "Protocols"

showing 10 items of 782 documents

Decentralized classification in societies of autonomous and heterogenous robots

2011

This paper addresses the classification problem for a set of autonomous robots that interact with each other. The objective is to classify agents that “behave” in “different way”, due to their own physical dynamics or to the interaction protocol they are obeying to, as belonging to different “species”. This paper describes a technique that allows a decentralized classification system to be built in a systematic way, once the hybrid models describing the behavior of the different species are given. This technique is based on a decentralized identification mechanism, by which every agent classifies its neighbors using only local information. By endowing every agent with such a local classifie…

distributed algorithm0106 biological sciencesSpecies classification0209 industrial biotechnologyEngineeringbusiness.industrymulti-robot systemInteraction protocolRoboticsMobile robot02 engineering and technologyAutonomous robotconsensus protocols010603 evolutionary biology01 natural sciencesComputer Science::Multiagent SystemsIdentification (information)020901 industrial engineering & automationSettore ING-INF/04 - AutomaticaRobotArtificial intelligenceSet (psychology)businessClassifier (UML)2011 IEEE International Conference on Robotics and Automation
researchProduct

Orthognathic surgery and aligners. A comparative assessment of periodontal health and quality of life in postsurgical orthodontic treatment with alig…

2023

Removable clear aligners have become very popular in the last few decades, but they are still little used in the field of orthognathic surgery (OS). The objective of this study was to compare periodontal health and quality of life (QoL) associated to postsurgical orthodontic treatment. Patients with dentofacial deformities undergoing OS were randomly allocated to receive postsurgical orthodontic treatment with either fixed orthodontic appliances or Invisalign. The main outcomes were periodontal health and QoL. Plaque index, probing depth and bleeding on probing were assessed as periodontal health indicators. QoL was assessed through the Orthognathic Quality of Life Questionnaire (OQLQ-22) a…

general surgerysurgical oncology postoperative complicationsperioperative careOtorhinolaryngologyclinical protocolsdental careSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.

2000

This paper studies the effects caused in human retinoblastoma Y79 cells by treatment with combinations of sodium butyrate, the inhibitor of topoisomerase I camptothecin and the inhibitor of 26S proteasome MG132. The combination of sodium butyrate and camptothecin resulted in a strong synergistic cytotoxicity, as revealed by combination indices of 0.77 and 0.52 calculated at IC(50) and IC(75). Synergistic interactions were also demonstrated for combinations of sodium butyrate and MG132, camptothecin and MG132 and for a combination of all three compounds. The cytotoxic effects observed after the combined treatments can be considered a consequence of apoptosis, as suggested by the appearance o…

medicine.drug_classCell SurvivalLeupeptinsSodiumchemistry.chemical_elementApoptosisButyrateBiologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132Antineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedHumansheterocyclic compoundsEnzyme InhibitorsRetinoblastomaCaspase 3TopoisomeraseRetinoblastomaSodium butyrateDrug SynergismGeneral Medicinemedicine.diseaseeye diseasesEnzyme ActivationButyrateschemistryBiochemistryProto-Oncogene Proteins c-bcl-2CaspasesCancer researchbiology.proteinCamptothecinTopoisomerase I InhibitorsTumor Suppressor Protein p53CamptothecinTopoisomerase inhibitormedicine.drugTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Anti-endothelin drugs in solid tumors

2010

Importance of the field: The endothelin (ET) axis, which includes the biological functions of ETs and their receptors, has played a physiological role in normal tissue, acting as a modulator of vasomotor tone, tissue differentiation and development, cell proliferation and hormone production. Interestingly, it also functions in the growth and progression of various tumors. Several researchers have identified the blockade of the ET-1 receptor as a promising therapeutic approach. Areas covered in this review: The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. In this neoplasia, it has shown antitumor activity, bone metastasis con…

medicine.hormoneEndothelin Receptor AntagonistsMalemedicine.medical_specialtyPyrrolidinesSettore MED/06 - Oncologia Medicaatrasentan endothelins prostate cancer zibotentanModels BiologicalEndothelinsProstate cancerchemistry.chemical_compoundDrug Delivery SystemsInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)ReceptorPharmacologyZibotentanbusiness.industryReceptors EndothelinEndothelinsAtrasentanBone metastasisProstatic NeoplasmsDrugs Investigationalmedicine.diseaseBlockadeEndocrinologychemistryAtrasentanCancer researchEndothelin receptorbusinessmedicine.drugSignal Transduction
researchProduct

Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?

2020

Abstract Aim This paper aims to analyze the usefulness of the G8 geriatric oncology questionnaire in patients with advanced/metastatic pancreatic adenocarcinoma (aPAC) and its possible association with different clinical outcomes. Methods Patients age > 70 years were screened with the G8 tool and treated with intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 for 3 consecutive weeks followed by one-week rest as prescribed after clinical evaluation by treating oncologists. Patient’s charts were evaluated for type and severity of toxicity, 2 cycle rate of completion, discontinuation rate, delays, dose reductions, and other outcomes response rates, progression-free, and overall su…

medicine.medical_specialtyAdenocarcinoma03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineGeriatric AssessmentAgedResponse rate (survey)business.industryGeriatric assessmentGemcitabine Maintenance Nab-paclitaxel Older adults Pancreatic cancerMetastatic Pancreatic Adenocarcinomamedicine.diseaseGemcitabineDiscontinuationPancreatic NeoplasmsOncologyGeriatric oncology030220 oncology & carcinogenesisToxicityGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the …

2013

Kast, Richard E. et al.

medicine.medical_specialtyCaptoprilTel avivMorpholinesArtesunateReviewGluconatesAngiotensinQuality of lifeAuranofinSertralineAntineoplastic Combined Chemotherapy ProtocolsDisulfiramTemozolomidemedicineRecurrent diseaseHumansIn patientNelfinavirTemozolomideBrain Neoplasmsbusiness.industrySuccinatesNeurokininCytotoxic chemotherapyUniversity hospitalmedicine.diseaseArtemisininsSurgeryDacarbazineKetoconazoleOncologyangiotensin aprepitant artesunate auranofin captopril cytokines disulfiram glioblastoma ketoconazole nelfinavir neurokinin sertraline temozolomideFamily medicineCytokinesNeoplasm Recurrence LocalGlioblastomabusinessAprepitantGlioblastomamedicine.drugOncotarget
researchProduct

A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor i…

1994

Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days. In the phase I part of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached. At the dose of 40mg/m2/day prolonged grade 4 leukopenia, severe proctitis, and grade 3 diarrhea represented the DLT. All subsequent partients were treated at the maximal tolerated dose of EDXR (35 mg/m2/day). In the group of 18 patients treated at 3…

medicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia Medicamedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineCarcinomaHumansRadiology Nuclear Medicine and imagingCyclophosphamideEpirubicinChemotherapyLeukopeniabusiness.industryCarcinomaHematologyGeneral MedicineLeukopeniaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryGranulocyte colony-stimulating factorSettore MED/18 - Chirurgia GeneraleRegimenTreatment OutcomeOncologyFluorouracilToxicityFemaleFluorouracilmedicine.symptombusinessmedicine.drugActa oncologica (Stockholm, Sweden)
researchProduct